Progress in Therapy of Lung Cancer
DOI:
https://doi.org/10.54097/wxpa7677Keywords:
lung cancer; pathogenesis; therapy; treatments.Abstract
Lung cancer has become one of the most common cancers worldwide, and it is also the main cause of cancer-related deaths. It is estimated that over 22 million new cases and 1.79 million deaths are caused by lung cancer each year. The theory of "airway field of injury" has been used to explain the pathogenesis of lung cancer, but its specific molecular mechanism is not clear yet. With the completion of comprehensive genomic analysis of lung cancer, modern medicine has revealed its genetic heterogeneity and complexity, and identified many oncogenic driving genes and molecular pathogenesis of lung cancer. At present, common treatment methods for lung cancer include chemotherapy, radiotherapy, targeted therapy, immunotherapy, and gene therapy. Each treatment has a unique mechanism and targets, but also has different advantages and disadvantages. Corresponding to different lung cancer patients, it is necessary to comprehensively consider their physiological health and economic status, choosing appropriate treatment strategies.
Downloads
References
Thun MJ, Carter BD, Feskanich D, et al. 50-Year Trends in Smoking-Related Mortality in the United States. New England Journal of Medicine. 2013;368(4):351-364.
Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, et al. Challenges to effective cancer control in China, India, and Russia. The Lancet Oncology. 2014;15(5):489-538.
Hernandez C, Huebener P, Schwabe RF. Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene. 2016;35(46):5931-5941.
Mayekar MK, Bivona TG. Current Landscape of Targeted Therapy in Lung Cancer. Clinical Pharmacology & Therapeutics. 2017;102(5):757-764.
Wistuba II, Gazdar AF. LUNG CANCER PRENEOPLASIA. Annual Review of Pathology: Mechanisms of Disease. 2006;1(1):331-348.
Kadara H, Wistuba II. Field Cancerization in Non–Small Cell Lung Cancer: Implications in Disease Pathogenesis. Proceedings of the American Thoracic Society. 2012;9(2):38-42.
Tang X, Shigematsu H, Bekele BN, et al. EGFR Tyrosine Kinase Domain Mutations Are Detected in Histologically Normal Respiratory Epithelium in Lung Cancer Patients. Cancer Research. 2005;65(17):7568-7572.
Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genetics. 2009;41(11):1238-1242.
Buchheidt D, Skladny H, Baust C, Hehlmann R. Systemic Infections with Candida sp. and Aspergillus sp. in Immunocompromised Patients with Hematological Malignancies: Current Serological and Molecular Diagnostic Methods. Chemotherapy. 2000;46(3):219-228.
Khuri FR, Cohen V. Molecularly Targeted Approaches to the Chemoprevention of Lung Cancer. Clinical Cancer Research. 2004;10(12):4249s-4253s.
Karthaus M, Doellmann T, Klimasch T, et al. Intensive Intravenous Amphotericin B for Prophylaxis of Systemic Fungal Infections. Chemotherapy. 2000;46(4):293-302.
Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: Molecular mechanisms of action. European Journal of Pharmacology. 2014; 740:364-378.
Olaussen KA, Postel-Vinay S. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Annals of Oncology. 2016;27(11):2004-2016.
Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed Disodium: A Novel Antifolate Clinically Active Against Multiple Solid Tumors. The Oncologist. 2001;6(4):363-373.
Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. European Journal of Cancer. 1998;34(10):1514-1521.
Clinical validation of a comprehensive cancer genomics analysis for lung cancer patients. | Journal of Clinical Oncology.
The Cancer Genome Atlas Research Network. Author Correction: Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2018;559(7715): E12-E12.
Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561-566.
Farago AF, Le LP, Zheng Z, et al. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 2015;10(12):1670-1674.
Jänne PA, Van Den Heuvel MM, Barlesi F, et al. Selumetinib Plus Docetaxel Compared with Docetaxel Alone and Progression-Free Survival in Patients with KRAS -Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. JAMA. 2017;317(18):1844.
Nair J, Nair A, Veerappan S, Sen D. Translatable gene therapy for lung cancer using Crispr CAS9—an exploratory review. Cancer Gene Therapy. 2020;27(3-4):116-124.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
